BioLine RX Ltd Market Cap ($8.58 Million)
Market Cap & Net Worth: BioLine RX Ltd (BLRX)
BioLine RX Ltd market cap. BioLine RX Ltd (TA:BLRX) has a market capitalization of $8.58 Million (ILA3.20 Billion) as of November 1, 2026. Listed on the TA stock exchange, this Israel-based company holds position #27342 globally and #386 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioLine RX Ltd's stock price ILA1.10 by its total outstanding shares 2909394790 (2.91 Billion). Also see BLRX cash flow metrics for how efficiently the company converts equity into cash flow.
BioLine RX Ltd Market Cap History (2015–2026)
BioLine RX Ltd market cap history from 2015 to 2026. Data shows change from $3.98 Billion to $8.58 Million (-43.22% CAGR). Check BLRX live share price for real-time trading data and today's change.
BioLine RX Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioLine RX Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BioLine RX Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.77x
BioLine RX Ltd's market cap is 9.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $296.40 Million | $4.80 Million | -$60.61 Million | 61.75x | N/A |
| 2024 | $49.92 Million | $28.94 Million | -$9.22 Million | 1.72x | N/A |
| 2025 | $12.48 Million | $1.28 Million | -$1.27 Million | 9.77x | N/A |
Competitor Companies of BLRX by Market Capitalization
Companies near BioLine RX Ltd in the global market cap rankings as of November 1, 2026. Also see BLRX asset base for a full breakdown of the balance sheet.
Key companies related to BioLine RX Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of BioLine RX Ltd (2015–2026)
Market capitalization of BioLine RX Ltd from 2015 to today. Between 2015 and today, BioLine RX Ltd's market cap moved from $3.98 Billion to $ 8.58 Million, with a yearly change of -43.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA8.58 Million | -31.25% |
| 2025 | ILA12.48 Million | -75.00% |
| 2024 | ILA49.92 Million | -83.16% |
| 2023 | ILA296.40 Million | +169.50% |
| 2022 | ILA109.98 Million | -67.59% |
| 2021 | ILA339.30 Million | -21.20% |
| 2020 | ILA430.56 Million | +0.73% |
| 2019 | ILA427.44 Million | -66.38% |
| 2018 | ILA1.27 Billion | -56.90% |
| 2017 | ILA2.95 Billion | +8.96% |
| 2016 | ILA2.71 Billion | -32.01% |
| 2015 | ILA3.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of BioLine RX Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.58 Million USD |
| MoneyControl | $8.58 Million USD |
| MarketWatch | $8.58 Million USD |
| marketcap.company | $8.58 Million USD |
| Reuters | $8.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioLine RX Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more